GlassScriptPhysician profile
Lillian A Johnson
NPI 1790163012
$661.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $135.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.10 | 2019-2020 | |
| Novo Nordisk INC | $60.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.38 | 2019-2020 | |
| Abbvie INC. | $41.52 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $32.89 | 2019 | |
| Merck Sharp & Dohme LLC | $32.87 | 2019 | |
| Pfizer INC. | $30.78 | 2019-2020 | |
| Lilly USA, LLC | $25.96 | 2019 | |
| Alkermes, INC. | $19.31 | 2019 | |
| Eisai INC. | $16.71 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.27 | 2019 | |
| Assertio Therapeutics, INC. | $14.98 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $14.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.